Agreement - July 3, 2026
AlzeCure enters an out-licensing and collaboration agreement with QuantumCell
AlzeCure Pharma has entered into an out-licensing and collaboration agreement with QuantumCell, a Danish tech-enabled biotech company, regarding the global rights to AlzeCure’s Alzheimer’s platform NeuroRestore, including the leading drug candidate ACD856.
Agreement - June 22, 2026
BioArctic and Lilly sign research and collaboration agreement
The company has entered into the agreement with Eli Lilly and Company regarding a potential new treatment combining BioArctic’s BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.
Agreement - June 12, 2026
Xbrane Biopharma and JOINN Biologics US enter strategic partnership
The two companies have entered into a strategic partnership featuring customized development services for Xdarzane, Xbrane's biosimilar candidate referencing Darzalex (daratumumab).
Agreement - June 9, 2026
AlzeCure Pharma enters collaboration and out-licensing agreement with Lilly
AlzeCure Pharma has entered into a collaboration and out-licensing agreement with the pharmaceutical company Eli Lilly and Company regarding the global rights to the Alzheimer’s project Alzstatin ACD680.
Agreement - June 2, 2026
Rayca Precision partners with ASAKE on AI-designed therapeutics
The Helsinki-based AI drug discovery company has paired with a US biotech in rare and metabolic disease.
Agreement - June 2, 2026
Camurus and Lilly sign deal on long-acting incretin therapies
Camurus has entered a global collaboration and license agreement with Eli Lilly and Company to develop long-acting incretin-based therapies for cardiometabolic diseases using its FluidCrystal technology platform.
